Ambroxol: the “scavenger” among expectorants

Ambroxol is a commonly used mucolytic agent in clinical practice. It reduces the viscosity of sputum by decomposing mucin fibers in sputum. It is suitable for respiratory diseases such as acute and chronic bronchitis. This article will start from four aspects: pharmacological effects, clinical application, product information and precautions, focusing on analyzing its expectorant mechanism and scientific medication principles, and also attaches a comparison table of major domestic and foreign manufacturers.

1. Pharmacological effects and clinical value

Ambroxol stimulates alveolar type II cells to secrete surfactant and activates ciliary movement at the same time, forming a dual effect of "promoting excretion-dilution". Research shows that it can reduce the viscosity of sputum by 40%-60% (Journal of Clinical Pharmacology 2021), and it is especially effective on white sticky phlegm. It should be noted that when used in combination with antibiotics, the concentration of amoxicillin and other drugs in the lung tissue may increase, and the dosage needs to be adjusted according to the doctor's advice.

2. Precision Medication Guide

The conventional dosage for adults is 30 mg/time, 3 times a day, and for children, it is calculated as 1.2 mg/kg/day. The Respiratory Branch of the Chinese Medical Doctor Association pointed out that when treating acute exacerbations of COPD, it is recommended to use it in combination with bronchodilators. You need to be alert to rare adverse reactions such as rash (incidence rate <0.1%). During the medication period, the daily water intake should be maintained at more than 1500ml to enhance the phlegm elimination effect.

3. Product market overview

4. Scientific understanding and summary

Ambroxol is used as a basic expectorant medication, and its efficacy has been recommended by the "Chinese Cough Diagnosis and Treatment Guidelines". However, it must be made clear that it cannot replace anti-infective treatment, and it should be disabled when there is blood in the sputum or an acute asthma attack. Only by correctly understanding the characteristics of the drug and using it rationally based on individual conditions can its role as a "scavenger" in the respiratory tract be maximized.

Quote sources:
1. "Expert Consensus on the Clinical Application of Ambroxol" (Respiratory Disease Branch of Chinese Medical Association, 2020)
2. Boehringer Ingelheim Pharmaceutical Instructions (2023 Edition)
3. National Medical Products Administration Announcement on Consistency Evaluation of Generic Drugs (NMPA, 2022)